PMID- 6476951
OWN - NLM
STAT- MEDLINE
DCOM- 19841004
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 38
IP  - 3
DP  - 1984 Sep
TI  - Five-year clinical experience with the Omniscience cardiac valve.
PG  - 275-80
AB  - Clinical data on the Omniscience cardiac valve prosthesis (sizes 19 to 31 mm) 
      were obtained from 326 patients (155, aortic valve replacement [AVR]; 125, mitral 
      valve replacement [MVR]; and 46, double-valve replacement) during a five-year 
      period (650 patient-years) with 96% accountability. Mean age was 56 +/- 12 years, 
      and 40% (130) of the patients were 61 years old or older. Thirty-one percent 
      (101) had prior or concomitant coronary artery bypass grafting procedures, 9% 
      (28) had a previous malfunctioning prosthesis, and 17% (57) had other cardiac 
      surgical procedures. Eighty percent were in New York Heart Association (NYHA) 
      Functional Class III or IV preoperatively. Early mortality was 10% (34). 
      Five-year actuarial thrombus-free rate is 96% for patients who underwent AVR and 
      95% for patients having MVR. Postoperatively, 89% (172/193) were in NYHA Class I 
      or II, and 84% (163/193) improved by at least one Functional Class. A 
      significantly high proportion of the postoperative hematological values fall 
      within normal ranges: red blood cell count, 94% (176/187); hematocrit, 88% 
      (166/188); and hemoglobin, 93% (176/190). Ninety-eight percent (287/292) are free 
      from clinical anemia. Four of the 5 patients with clinical anemia had a 
      preoperative history of this condition. Levels of lactic dehydrogenase in 3 
      patients suggested the probable presence of clinically significant hemolysis, 
      although all 3 have normal hematological values. Actuarial five-year survival for 
      patients who underwent AVR or MVR are similar (82% and 80%, respectively), 
      indicating satisfactory and comparable levels of safety and performance.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - DeWall, R
AU  - DeWall R
FAU - Pelletier, L C
AU  - Pelletier LC
FAU - Panebianco, A
AU  - Panebianco A
FAU - Hicks, G
AU  - Hicks G
FAU - Schuster, B
AU  - Schuster B
FAU - Bonan, R
AU  - Bonan R
FAU - Martineau, J P
AU  - Martineau JP
FAU - Yip, L
AU  - Yip L
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Hemoglobins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aortic Valve
MH  - Erythrocyte Count
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Valve Diseases/blood/*surgery
MH  - *Heart Valve Prosthesis/adverse effects/mortality
MH  - Hematocrit
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve
MH  - Thromboembolism/etiology
EDAT- 1984/09/01 00:00
MHDA- 1984/09/01 00:01
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 1984/09/01 00:01 [medline]
PHST- 1984/09/01 00:00 [entrez]
AID - S0003-4975(10)62251-5 [pii]
AID - 10.1016/s0003-4975(10)62251-5 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1984 Sep;38(3):275-80. doi: 10.1016/s0003-4975(10)62251-5.